DRUG · Mapped RxNorm record
Darolutamide Oral Tablet [Nubeqa]
Normalized identity: darolutamide Oral Tablet [Nubeqa]View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
NCT05900973
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
Sponsors & collaborators
D'Or Institute for Research and Educationlead sponsor
Bayercollaborator
RPH Central Pharmacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05900973 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.